{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:04:23Z","timestamp":1782839063022,"version":"3.54.5"},"reference-count":27,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the effect of topical instillation of pegaptanib sodium upon inflammatory angiogenesis induced in the rabbit cornea by alkaline cauterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Inflammatory angiogenesis was induced by alkaline (sodium hydroxide) cauterization in the corneas of 29 male New Zealand rabbits. The animals were divided into 4 groups: a control group treated with 0.5% carboxymethylcellulose sodium eye drops, a group treated with 1.0% prednisolone acetate eye drops, a group treated with 0.5% pegaptanib sodium diluted in 15\u2009mL 0.5% carboxymethylcellulose sodium, and a group treated with 1.0% pegaptanib sodium diluted in 15\u2009mL 0.5% carboxymethylcellulose sodium. After cauterization, eye drops were administered every 12 hours for 21 days. The animals were evaluated every 3 days after cauterization, and the newly formed vessels were quantified from photographs. The treatment effectiveness was analyzed with 3 parameters of antiangiogenic response: neovascularization area (NA), total vascular length (TVL), and number of blood vessels (BVN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Average NA, TVL, and BVN values were significantly higher in both pegaptanib groups than in the prednisolone group. A nonstatistically significant reduction in parameters on days 18 and 21 was the minimum achieved in both pegaptanib groups. The efficacy of the treatments in relation to the control was significantly greater in the prednisolone group than in the 0.5% pegaptanib group or the 1.0% pegaptanib group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Topical instillation of 0.5% and 1.0% pegaptanib sodium diluted in 15\u2009mL 0.5% carboxymethylcellulose sodium had no inhibitory effect on corneal neovascularization in this rabbit model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2020.0010","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T12:22:54Z","timestamp":1619180574000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits"],"prefix":"10.1177","volume":"37","author":[{"given":"Newton","family":"Andrade","sequence":"first","affiliation":[{"name":"Research and Development Center for Medicines, Federal University of Ceara, Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Crispim Ribeiro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Christus University Center (Unichristus), Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Matheus","family":"Ara\u00fajo e Silva","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Christus University Center (Unichristus), Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingos","family":"Savio","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Christus University Center (Unichristus), Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Vagnaldo","family":"Fechine","sequence":"additional","affiliation":[{"name":"Research and Development Center for Medicines, Federal University of Ceara, Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoel Odorico","family":"de Moraes","sequence":"additional","affiliation":[{"name":"Research and Development Center for Medicines, Federal University of Ceara, Fortaleza, Cear\u00e1, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2007.01572.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.107912"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200108000-00002"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009071601454"},{"key":"e_1_3_3_6_2","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp W.","year":"2000","unstructured":"Philipp W., , Speicher L., , and Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest. Ophthalmol. Vis. Sci. 41:2514\u20132522, 2000.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_7_2","first-page":"103","article-title":"Kuo, H.K., Tai, M.H., et al","volume":"28","author":"Wu P.C.","year":"2009","unstructured":"Wu P.C. Kuo, H.K., Tai, M.H., et al. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea., 28:103\u2013104, 2009.","journal-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0976-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31822480f9"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1129"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-009-1934-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200204000-00002"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0570"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.052"},{"key":"e_1_3_3_15_2","first-page":"361","article-title":"Ranibizumab: phase III clinical trial results","volume":"19","author":"Rosenfeld P.J.","year":"2006","unstructured":"Rosenfeld P.J., , Rich R.M., , and Lalwani G.A. Ranibizumab: phase III clinical trial results. Ophthalmol. Clin. North. Am. 19:361\u2013372, 2006.","journal-title":"Ophthalmol. Clin. North. Am"},{"key":"e_1_3_3_16_2","first-page":"2805","article-title":"Jr., et al","volume":"351","author":"Gragoudas E.S.","year":"2004","unstructured":"Gragoudas E.S., , Adamis A.P., , Cunningham E.T. Jr., et al. VEGF inhibition study in ocular neovascularization clinical trial group\u2014pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351:2805\u20132816, 2004.","journal-title":"VEGF inhibition study in ocular neovascularization clinical trial group\u2014pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.132597"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.012"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0978-9"},{"key":"e_1_3_3_20_2","first-page":"2602487","article-title":"Simultaneous subconjunctival triamcinolone and bevacizumab injections for management of blepharokeratoconjunctivitis in children","volume":"2018","author":"Nguyen C.L.","year":"2018","unstructured":"Nguyen C.L., , Chen T.S., , Tran K., , Smith J.E.H., , and Lewis N. Simultaneous subconjunctival triamcinolone and bevacizumab injections for management of blepharokeratoconjunctivitis in children. Case. Rep. Ophthalmol. Med. 2018:2602487, 2018.","journal-title":"Case. Rep. Ophthalmol. Med"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1159\/000337137"},{"key":"e_1_3_3_22_2","first-page":"S3418","article-title":"VEGF-immunoreactivity in human corneal buttons with neovascularization","volume":"39","author":"Cursiefen C.","year":"1998","unstructured":"Cursiefen C., , Rummelt C., , and Kuchle M. VEGF-immunoreactivity in human corneal buttons with neovascularization. ARVO abstracts. Invest. Ophthalmol. Vis. Sci., 39:S3418, 1998.","journal-title":"ARVO abstracts. Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0102-86502005000100010"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000220768.11778.60"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000178731.42187.46"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0195"},{"key":"e_1_3_3_27_2","first-page":"136","article-title":"Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model","volume":"6","author":"Akar E.E.","year":"2013","unstructured":"Akar E.E., , Oner V., , K\u00fc\u00e7\u00fckerd\u00f6nmez C., , and Ayd\u0131n Akova Y. Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model. Int. J. Ophthalmol. 6:136\u2013140, 2013.","journal-title":"Int. J. Ophthalmol"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2001.1007"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2020.0010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2020.0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:43:58Z","timestamp":1777646638000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2020.0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6,1]]}},"alternative-id":["10.1089\/jop.2020.0010"],"URL":"https:\/\/doi.org\/10.1089\/jop.2020.0010","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}